| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
TTA-Q6(isomer) targets T-type calcium channels (Ca2+ channels), which are voltage-gated calcium channels involved in various physiological processes including neuronal excitability, cardiac pacemaking, and pain signaling. As an antagonist of T-type calcium channels, this compound blocks calcium ion influx through these channels. The isomer may exhibit different pharmacological properties compared to the parent compound.
|
|---|---|
| ln Vitro |
In vitro activity of TTA-Q6(isomer) is expected to be similar to TTA-Q6, which functions as a selective T-type Ca2+ channel antagonist. The compound inhibits T-type calcium channel activity in electrophysiological assays. Its activity is typically assessed by measuring the reduction in calcium currents in cells expressing T-type calcium channels.
|
| ln Vivo |
In vivo activity data for TTA-Q6(isomer) are limited, as it is primarily used as a research tool for in vitro electrophysiological studies. TTA-Q6 (the parent compound) has potential applications in treating neurological disorders. TTA-Q6(isomer) may be used to study the stereospecific effects of T-type calcium channel antagonists.
|
| Enzyme Assay |
In vitro receptor binding assays for TTA-Q6(isomer) are performed using membrane preparations expressing T-type calcium channels. Radioligand binding assays are used to measure the compound's affinity for T-type calcium channels. These cell-free assays provide quantitative data on the compound's binding affinity and selectivity.
|
| Cell Assay |
In vitro cellular assays for TTA-Q6(isomer) are performed using cells expressing T-type calcium channels. Patch-clamp electrophysiology is used to measure calcium currents in the presence of the compound. The reduction in calcium current amplitude is quantified to determine the compound's inhibitory potency. These assays provide functional evidence of T-type calcium channel antagonism.
|
| Animal Protocol |
In vivo animal experimental protocols for TTA-Q6(isomer) are not extensively documented in the available literature. As a research compound, in vivo studies would typically involve administration to animal models of neurological disorders. The compound would be administered via appropriate routes, and efficacy would be assessed using behavioral or electrophysiological endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of TTA-Q6(isomer) have not been systematically characterized. The compound has a molecular weight of 405.80 and molecular formula C20H15ClF3N3O. It is an isomer of TTA-Q6. Further PK studies are needed to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for TTA-Q6(isomer) are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive toxicology studies. The compound is intended for research purposes only. Standard laboratory safety precautions should be followed when handling this compound.
|
| Additional Infomation |
TTA-Q6(isomer) is a selective T-type calcium channel antagonist with CAS number 910484-32-1, molecular formula C20H15ClF3N3O, and molecular weight 405.80. It is the (R)-isomer of TTA-Q6 and is used in neurological research to study T-type calcium channel function. This product is for research use only.
|
| Molecular Formula |
C20H15CLF3N3O
|
|---|---|
| Molecular Weight |
405.800813913345
|
| Exact Mass |
405.085
|
| CAS # |
910484-32-1
|
| Related CAS # |
TTA-Q6;910484-28-5
|
| PubChem CID |
124404458
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
28
|
| Complexity |
665
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(N1C(=O)NC2C=CC(=CC=2[C@]1(C1C=CC(C#N)=CC=1)C1CC1)Cl)C(F)(F)F
|
| InChi Key |
OVRNWJYZCIAMGV-FQEVSTJZSA-N
|
| InChi Code |
InChI=1S/C20H15ClF3N3O/c21-15-7-8-17-16(9-15)20(14-5-6-14,13-3-1-12(10-25)2-4-13)27(18(28)26-17)11-19(22,23)24/h1-4,7-9,14H,5-6,11H2,(H,26,28)/t20-/m0/s1
|
| Chemical Name |
4-[(4R)-6-chloro-4-cyclopropyl-2-oxo-3-(2,2,2-trifluoroethyl)-1H-quinazolin-4-yl]benzonitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~308.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.13 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4643 mL | 12.3213 mL | 24.6427 mL | |
| 5 mM | 0.4929 mL | 2.4643 mL | 4.9285 mL | |
| 10 mM | 0.2464 mL | 1.2321 mL | 2.4643 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
